Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the benchmark index within the next six months [2][8]. Core Insights - The company reported a revenue of 454.6 billion yuan for 2025, representing a year-on-year growth of 15.8%, and a net profit attributable to shareholders of 191.5 billion yuan, which is a significant increase of 102.6% [4][8]. - The Chemistry business showed stable growth with a revenue of 364.7 billion yuan in 2025, up 25.5%, while the TIDES business experienced remarkable growth, generating 113.7 billion yuan, a 96.0% increase [5][8]. - The company has a strong order backlog of 580 billion yuan, reflecting a year-on-year increase of 28.8% as of the end of 2025, with guidance for 2026 indicating an expected revenue of 513-530 billion yuan, representing a growth of 18-22% [7][8]. Summary by Relevant Sections Financial Performance - For Q4 2025, the company achieved a revenue of 126.0 billion yuan, up 9.2%, and a net profit of 70.8 billion yuan, which is a 142.5% increase [4]. - The overall gross margin for 2025 was 48.2%, an increase of 6.6 percentage points, while the Non-IFRS net profit margin was 32.9%, up 5.9 percentage points [7]. Business Segments - The Testing business generated 40.4 billion yuan in revenue for 2025, a growth of 4.7%, but faced margin pressure with a gross margin of 30.5%, down 5.7 percentage points [6]. - The Biology business reported a revenue of 26.8 billion yuan, up 5.5%, with a gross margin of 37.0%, down 1.9 percentage points [6]. Future Projections - Revenue projections for 2026, 2027, and 2028 are estimated at 521.6 billion yuan, 605.9 billion yuan, and 694.5 billion yuan, respectively, with year-on-year growth rates of 14.7%, 16.2%, and 14.6% [8][11]. - The forecasted net profit for 2026 is 163.9 billion yuan, reflecting a decrease of 14.4% year-on-year, followed by increases of 17.7% and 16.1% in the subsequent years [8][11].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the benchmark index within the next six months [2][8]. Core Insights - The company reported a revenue of 45.46 billion yuan for 2025, representing a year-on-year growth of 15.8%, and a net profit attributable to shareholders of 19.15 billion yuan, which is a significant increase of 102.6% [4][8]. - The Chemistry business showed stable growth with a revenue of 36.47 billion yuan, up 25.5%, while the TIDES business experienced remarkable growth, with revenue reaching 11.37 billion yuan, up 96.0% [5][8]. - The company has a strong order backlog of 58 billion yuan, reflecting a year-on-year increase of 28.8% [7]. Financial Performance Summary - The company’s gross margin for 2025 was 48.2%, an increase of 6.6 percentage points, and the Non-IFRS net profit margin was 32.9%, up 5.9 percentage points [7]. - For Q4 2025, the revenue was 12.6 billion yuan, with a net profit of 7.08 billion yuan, marking a year-on-year increase of 142.5% [4][6]. - The projected revenues for 2026, 2027, and 2028 are 52.16 billion yuan, 60.59 billion yuan, and 69.45 billion yuan, respectively, with expected growth rates of 14.7%, 16.2%, and 14.6% [8][11]. Business Segment Performance - The Testing business generated a revenue of 4.04 billion yuan in 2025, growing by 4.7%, but faced margin pressure with a gross margin of 30.5%, down 5.7 percentage points [6]. - The Biology business reported a revenue of 2.68 billion yuan, up 5.5%, with a gross margin of 37.0%, down 1.9 percentage points [6]. Valuation Metrics - The company’s projected P/E ratios for 2026, 2027, and 2028 are 17, 15, and 12, respectively, indicating a favorable valuation outlook [8][11]. - The projected EPS for the same years is 5.49 yuan, 6.46 yuan, and 7.50 yuan [11]. Conclusion - The report highlights the company's strong market position as a leading integrated drug development service platform, with expectations for continued growth in its core Chemistry business and stable profitability [8].

Company and Industry Summary Company: WuXi AppTec (药明康德) Key Points - **Revenue Growth**: WuXi AppTec has announced a revenue forecast for 2025 of 45.46 billion yuan, representing a year-on-year increase of 15.8%. The revenue from continuing operations is expected to grow at a rate of 21.4% [1] - **Guidance vs. Actuals**: The company's guidance for 2025 was between 43.5 billion and 44 billion yuan, with a growth rate for continuing operations projected at 17-18%. The actual forecast exceeds this guidance, indicating strong performance [1] - **Quarterly Performance**: In Q4 2025, the company is expected to maintain a sequential revenue growth, sustaining over 20% growth for the year despite a high base in Q4 2024. The Non-IFRS net profit margin for Q4 2025 is projected to be stable at 35.1%, slightly lower than Q3 2025 [1] Industry: TIDES and CDMO Key Points - **TIDES Business Growth**: The TIDES business is expected to see revenue growth exceeding 90% in 2025. With large orders anticipated in 2026, the Chemistry business is also expected to maintain rapid growth and an upward trend in gross margins. The recovery of domestic demand and stable overseas demand are likely to enhance profit margins further [2] - **Global Position in CDMO**: WuXi AppTec has established itself as a leading player in the global small molecule CDMO sector. In 2025, the company supported the approval of 8 out of 30 new small molecule drugs by the FDA. Additionally, it has supported 11 out of 56 peptides and 12 out of 36 small molecules in the global GLP-1 drug category [2] - **Potential Beneficiaries**: The company is positioned to be a major beneficiary of future high-potential drugs such as oral GLP-1 and siRNA, which are expected to see significant market uptake [2]

Group 1 - The core viewpoint of the report is that Zhongyou Securities has given WuXi AppTec (603259.SH, latest price: 91.13 yuan) a buy rating due to its strong business performance [2] - The Chemistry business revenue continues to grow rapidly, while the Testing business revenue has stabilized [2] - The company has maintained a rapid growth in its order backlog and has raised its full-year revenue guidance [2]